Sanofi India is currently trading at Rs. 4201.00, up by 16.30 points or 0.39% from its previous closing of Rs. 4184.70 on the BSE.
The scrip opened at Rs. 4218.00 and has touched a high and low of Rs. 4262.00 and Rs. 4160.45 respectively. So far 261 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 4651.10 on 13-Nov-2015 and a 52 week low of Rs. 3090.00 on 27-Apr-2015.
Last one week high and low of the scrip stood at Rs. 4400.00 and Rs. 4113.00 respectively. The current market cap of the company is Rs. 9678.39 crore.
The promoters holding in the company stood at 60.40% while Institutions and Non-Institutions held 29.08% and 10.53% respectively.
Sanofi India has reported 29.95% rise in its net profit after exceptional items at Rs 120.20 crore as compared to Rs 92.50 crore for the same quarter in the previous year. The company’s total income has increased by 10.25% to Rs 581.13 crore for the quarter under review from Rs 527.10 crore for the corresponding quarter of the previous year.
For the full year, the company has reported 21.92% rise in its net profit after exceptional items at Rs 321.50 crore for FY15 as compared to Rs 263.70 crore in FY14. The company’s total income has increased by 9.93% to Rs 2244.50 crore for FY15 from Rs 2041.80 crore for the previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: